CRA provided expert reports and testimony in several cases involving improper diversion of diabetes test strips. CRA’s damages analyses quantified the difference in profits earned on legitimate sales of test strips in the U.S. retail market as compared to profits earned on the diverted test strips (for example, those sold in international markets or those intended for other patient groups in the U.S.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...